Skip to Content

DiaMedica Therapeutics Inc DMAC

Morningstar Rating
$2.22 +0.06 (2.78%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

DMAC is trading at a 247% premium.
Price
$2.16
Fair Value
$2.52
Uncertainty
Extreme
1-Star Price
$18.82
5-Star Price
$9.38
Economic Moat
Pxclt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DMAC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.16
Day Range
$2.142.29
52-Week Range
$1.944.75
Bid/Ask
$2.19 / $2.32
Market Cap
$84.28 Mil
Volume/Avg
28,253 / 37,354

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
19

Comparables

Valuation

Metric
DMAC
ABOS
CELC
Price/Earnings (Normalized)
Price/Book Value
1.770.533.67
Price/Sales
Price/Cash Flow
Price/Earnings
DMAC
ABOS
CELC

Financial Strength

Metric
DMAC
ABOS
CELC
Quick Ratio
17.9329.8310.64
Current Ratio
18.1430.2011.23
Interest Coverage
−13.89
Quick Ratio
DMAC
ABOS
CELC

Profitability

Metric
DMAC
ABOS
CELC
Return on Assets (Normalized)
−35.87%−19.28%−40.23%
Return on Equity (Normalized)
−37.97%−21.04%−56.35%
Return on Invested Capital (Normalized)
−37.64%−24.75%−44.81%
Return on Assets
DMAC
ABOS
CELC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
KkvwhkystHhtkz$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
ZhpswgsFdqjmt$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
FcxjsxxFqdtwx$116.0 Bil
Moderna Inc
MRNA
XyymhwrhbGkw$51.1 Bil
argenx SE ADR
ARGX
FhmwmjtgVrd$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
GsbwgrzrnTsfnbd$21.0 Bil
BioNTech SE ADR
BNTX
NhydftrHgfc$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
LfvvprdqWfpcpny$15.9 Bil
United Therapeutics Corp
UTHR
YkyryzyRpq$14.0 Bil
Incyte Corp
INCY
LfxdnqgdLcrrdp$12.5 Bil

Sponsor Center